Cyclacel shareholders authorize reverse stock split at 1-for-3 to 1-for-15 ratio

Proposal 2 The Company’s stockholders approved an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.

Item 5.07. Submission of Matters to a Vote of Security Holders. Cyclacel Pharmaceuticals, Inc. (the “Company”) held a Special Meeting on December 8, 2023 at 9:30 a.m. Eastern Time in virtual format. Of the Company’s 12,642,822 shares of common stock issued and outstanding and eligible to vote as of the record date of November 6, 2023, 7,315,280 shares, or approximately 57.86% of the eligible shares of common stock, were present virtually or represented by proxy. A quorum was present for all matters. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 14, 2023. The following actions were taken at the Special Meeting: Proposal 1 The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-3 and not greater than 1-for-15, with the exact ratio to